Current Management of Refractory Germ Cell Tumors and Future Directions.

about

Current Management of Refractory Germ Cell Tumors and Future Directions.

Item

http://www.wikidata.org/entity/Q38755132

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current Management of Refractory Germ Cell Tumors and Future Directions.

@en

type

Item

label

Current Management of Refractory Germ Cell Tumors and Future Directions.

@en

prefLabel

Current Management of Refractory Germ Cell Tumors and Future Directions.

@en

P1476

Current Management of Refractory Germ Cell Tumors and Future Directions.

@en

P2093

Alicia K Morgans

http://www.w3.org/2001/XMLSchema#string

Austin Kirschner

http://www.w3.org/2001/XMLSchema#string

J Clayton Allen

http://www.w3.org/2001/XMLSchema#string

Kristen R Scarpato

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.

Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.

Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors.

Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.

Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.

Ifosfamide in refractory male germ cell tumors.

Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germin

Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial.

P2888

s11912-017-0572-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-017-0572-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083852168

http://www.w3.org/2001/XMLSchema#string

P698

28220447

http://www.w3.org/2001/XMLSchema#string